Search Result
Results for "Antibody Samplers Inhibitors" in MCE Product Catalog:
9865
Inhibitors & Agonists
19
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-P9917
-
|
Tocilizumab
Anti-Human IL6R, Humanized Antibody
|
Interleukin Related
|
Cancer
Inflammation/Immunology
|
|
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
|
-
- HY-P9803
-
|
Anti-SARS-80R mAb
SARS-80R; SARS Antibody-80R
|
SARS-CoV
|
Infection
|
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells.
|
-
- HY-P9801
-
|
Anti-Spike-RBD mAb
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment.
|
-
- HY-P9807
-
-
- HY-P9805
-
|
Anti-MERS-3A1 mAb
MERS-3A1; MERS Antibody-3A1
|
SARS-CoV
|
Infection
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor.
|
-
- HY-P9802
-
|
Anti-Spike-RBD Single Domain mAb
SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity.
|
-
- HY-P9906
-
|
Bevacizumab
Anti-Human VEGF, Humanized Antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
- HY-P9908
-
-
- HY-U00439
-
-
- HY-P9907
-
|
Trastuzumab
Anti-Human HER2, Humanized Antibody
|
EGFR
|
Cancer
|
|
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
- HY-P9909
-
-
- HY-P9804
-
|
Anti-MERS-2E6 mAb
MERS-2E6; MERS Antibody-2E6
|
SARS-CoV
|
Infection
|
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
|
-
- HY-108730
-
-
- HY-P9911
-
|
Vedolizumab
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
- HY-P9806
-
|
Anti-MERS-D12 mAb
MERS-D12; MERS Antibody-D12
|
SARS-CoV
|
Infection
|
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding.
|
-
- HY-131326
-
-
- HY-18286
-
|
NCGC00229600
|
TSH Receptor
|
Endocrinology
|
|
NCGC00229600 is an allosteric inverse agonist of thyrotropin receptor (TSHR). NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously expressed in Graves' disease.
|
-
- HY-15583
-
-
- HY-132158
-
-
- HY-131955
-
-
- HY-118870
-
-
- HY-131005
-
-
- HY-138633
-
-
- HY-138634
-
-
- HY-P9902
-
|
Pembrolizumab
MK-3475; Lambrolizumab
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
|
-
- HY-U00439A
-
|
Protein kinase inhibitors 1 hydrochloride
(E)-5-((2-Oxo-6'-(piperazin-1-yl)-1,2-dihydro-[3,3'-bipyridin]-5-yl)methylene)thiazolidine-2,4-dione hydrochloride
|
DYRK
|
Cancer
|
|
Protein kinase inhibitors 1 hydrochloride is a potent HIPK2 inhibitor, with IC50s of 136 and 74 nM for HIPK1 and HIPK2, and a Kd of 9.5 nM for HIPK2.
|
-
- HY-P9912
-
|
Pertuzumab
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
- HY-N3522
-
|
Platycoside E
|
Others
|
Inflammation/Immunology
|
|
Platycoside E is a platycodigenin-type saponin isolated from the root of Platycodon grandiflorum with haemolytic activity and adjuvant potential. Platycoside E promotes the production of the sera OVA-specific IgG2a and IgG2b antibody in the ovalbumin (OVA)-immunized mice.
|
-
- HY-138635
-
-
- HY-138636
-
-
- HY-121879
-
-
- HY-W019939
-
|
Hydroxy-PEG10-Boc
|
ADC Linker
|
Cancer
|
|
Hydroxy-PEG10-Boc is extacted from patent CN108707228 (example 0024). Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel (HY-B0015) or docetaxel (HY-B0011).
|
-
- HY-P9905
-
|
Cetuximab
C225
|
EGFR
|
Cancer
|
|
Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity.
|
-
- HY-138632
-
-
- HY-19373
-
-
- HY-P9919
-
|
Durvalumab
MEDI 4736
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
|
-
- HY-P9923
-
|
Benralizumab
MEDI-563; BIW-8405
|
Interleukin Related
|
Inflammation/Immunology
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.
|
-
- HY-W012037
-
|
8-Hydroxyquinoline hemisulfate
8-Quinolinol hemisulfate
|
Bacterial
Antibiotic
|
Infection
|
|
8-Hydroxyquinoline hemisulfate (8-Quinolinol hemisulfate) is a monoprotic bidentate chelating agent, exhibits antiseptic, disinfectant, and pesticide properties, functioning as a transcription inhibitor.
|
-
- HY-P9903
-
|
Nivolumab
BMS-936558; ONO-4538; MDX-1106
|
PD-1/PD-L1
|
Cancer
|
|
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
|
-
- HY-50730
-
|
Asparagusic acid
|
Parasite
|
Infection
|
|
Asparagusic acid is a sulfur-containing flavor component produced by asparagus plants, with anti-parasitic effect. Asparagusic acid is a plant growth inhibitor.
|
-
- HY-115292
-
|
Simvastatin hydroxy acid sodium
Tenivastatin sodium; Simvastatin Impurity A sodium
|
HMG-CoA Reductase (HMGCR)
|
Cancer
|
|
Simvastatin hydroxy acid sodium (Tenivastatin sodium; Simvastatin Impurity A sodium) is an active hydrolytic metabolite of Simvastatin (HY-17502). Simvastatin shows a inhibition of HMG-CoA reductase with a Ki value of 0.12 nM.
|
-
- HY-P9904
-
|
Atezolizumab
MPDL3280A
|
PD-1/PD-L1
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
- HY-135813
-
|
LtaS-IN-1
|
Bacterial
|
Infection
|
|
LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely.
|
-
- HY-101918
-
|
DS-1040 Tosylate
|
Others
|
Cardiovascular Disease
|
|
DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.
|
-
- HY-16787
-
|
ICA-121431
|
Sodium Channel
|
Cardiovascular Disease
|
|
ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Nav) blocker, shows equipotent selectivity for human Nav1.1 and Nav1.3 subtypes with IC50 values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Nav1.2 (IC50=240 nM) and 1,000 fold selectivity against Nav1.4, Nav1.6, and the TTX-resistant human Nav1.5 and Nav1.8 channels (IC50s >10 µM).
|
-
- HY-18728
-
-
- HY-125957
-
|
A-3 hydrochloride
|
PKA
Casein Kinase
CaMK
PKC
|
Others
|
|
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively.
|
-
- HY-102090
-
-
- HY-P9921
-
|
Trastuzumab emtansine
Ado-Trastuzumab emtansine; PRO132365; T-DM 1
|
EGFR
|
Cancer
|
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer.
|
-
- HY-P9949
-
|
Reslizumab
Sch 55700
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.
|
-
- HY-P1783A
-
|
M2e, human TFA
|
Influenza Virus
|
Infection
|
|
M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A.
|
-
- HY-135682
-
-
- HY-P1783
-
|
M2e, human
|
Influenza Virus
|
Infection
|
|
M2e, human, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A, which is a valid and versatile vaccine candidate to protect against any strain of human influenza A.
|
-
- HY-19792
-
|
Mertansine
DM1; Maytansinoid DM1
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC).
|
-
- HY-122470
-
|
Stampidine
|
Reverse Transcriptase
HIV
|
Infection
|
|
Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) and primary clinical isolates with IC50s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC50s of 8.7 nM and 11.2 nM, respectively.
|
-
- HY-130082
-
|
DM4-SMe
|
ADC Cytotoxin
Microtubule/Tubulin
|
Cancer
|
|
DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC50 of 0.026 nM.
|
-
- HY-11007
-
|
GNF-2
|
Bcr-Abl
SARS-CoV
|
Cancer
|
|
GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM .
|
-
- HY-15581
-
-
- HY-108831
-
|
Natalizumab
|
Integrin
|
Inflammation/Immunology
|
|
Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.
|
-
- HY-P9970
-
-
- HY-P9920
-
|
Ramucirumab
|
VEGFR
|
Cancer
|
|
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.
|
-
- HY-12454
-
|
DM4
|
Microtubule/Tubulin
|
Cancer
|
|
DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody drug conjugate.
|
-
- HY-130081
-
|
DM3-SMe
|
ADC Cytotoxin
Microtubule/Tubulin
|
Cancer
|
|
DM3-SMe is a maytansine derivative and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM3-SMe shows highly cytotoxic activity in vitro with an IC50 of 0.0011 nM.
|
-
- HY-17422
-
|
Acyclovir
Aciclovir; Acycloguanosine
|
HSV
Bacterial
Apoptosis
Antibiotic
|
Cancer
Infection
|
|
Acyclovir (Aciclovir) is a guanosine analogue and an orally active antiviral agent. Acyclovir inhibits HSV-1 (IC50 of 0.85 μM), HSV-2 (IC50 of 0.86 μM) and varicella-zoster virus. Acyclovir can be phosphorylated by viral thymidine kinase (TK), and Acyclovir triphosphate interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate and obligatory chain termination. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia.
|
-
- HY-130080
-
|
DM3
Maytansinoid DM3
|
ADC Cytotoxin
Microtubule/Tubulin
|
Cancer
|
|
DM3 (Maytansinoid DM3) is a maytansine analog bearing disulfide or thiol groups and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs).
|
-
- HY-128960
-
-
- HY-135660
-
-
- HY-122907
-
|
JNJ4796
|
Influenza Virus
|
Infection
|
|
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs).
|
-
- HY-15582
-
|
Auristatin E
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.
|
-
- HY-15579S
-
|
D8-MMAF
Monomethylauristatin F D8
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride. MMAF Hydrochloride, a potent tubulin polymerization inhibitor, is used as a antitumor agent and a cytotoxic component of antibody-drug conjugates (ADCs).
|
-
- HY-138298
-
|
Trastuzumab deruxtecan
DS-8201; DS-8201a
|
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
|
-
- HY-130107
-
-
- HY-129365
-
|
SNPB
|
ADC Linker
|
Cancer
|
|
SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).
|
-
- HY-128871
-
|
VCP-Eribulin
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based drug for antibody conjugates.
|
-
- HY-130083
-
-
- HY-15162
-
|
Monomethyl auristatin E
MMAE; SGD-1010
|
Microtubule/Tubulin
ADC Cytotoxin
Apoptosis
|
Cancer
|
|
Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
|
-
- HY-42146
-
|
BMPS
|
ADC Linker
|
Cancer
|
|
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-129376
-
-
- HY-19318
-
-
- HY-19839
-
-
- HY-126519
-
-
- HY-128954
-
-
- HY-112100
-
|
PAC
|
Estrogen Receptor/ERR
PROTAC-linker Conjugate for PAC
|
Cancer
|
|
PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
|
-
- HY-126350
-
|
CL2-SN-38
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CL2-SN-38 is a part of the antibody drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is a DNA topoisomerase I inhibitor. The anti-Trop-2 hRS7-CL2A-SN-38 ADC provides significant and specific antitumor effects against a range of human solid tumor types.
|
-
- HY-129366
-
|
PDB-Pfp
|
ADC Linker
|
Cancer
|
|
PDB-Pfp is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-129375
-
-
- HY-44235
-
-
- HY-129373
-
-
- HY-126667
-
-
- HY-15579A
-
|
MMAF hydrochloride
Monomethylauristatin F hydrochloride
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
|
-
- HY-125586
-
|
β-Amanitin
|
DNA/RNA Synthesis
ADC Cytotoxin
|
Cancer
|
|
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs).
|
-
- HY-126498
-
-
- HY-129369
-
|
SPDMB
|
ADC Linker
|
Cancer
|
|
SPDMB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).
|
-
- HY-12448
-
|
SPDB
|
ADC Linker
|
Cancer
|
|
SPDB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).
|
-
- HY-129368
-
|
SPDMV
|
ADC Linker
|
Cancer
|
|
SPDMV is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).
|
-
- HY-126511
-
-
- HY-133540
-
-
- HY-126512
-
-
- HY-129370
-
-
- HY-128927
-
-
- HY-108847
-
|
Etanercept
|
TNF Receptor
|
Inflammation/Immunology
|
|
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
|
-
- HY-78931
-
|
Boc-Dap-NE
|
ADC Linker
|
Cancer
|
|
Boc-Dap-NE, a dipeptide, is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-136095
-
-
- HY-130111
-
-
- HY-44246
-
-
- HY-140014
-
|
Val-Cit
|
ADC Linker
|
Cancer
|
|
Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-101151
-
-
- HY-128970
-
-
- HY-116270
-
-
- HY-19318A
-
-
- HY-126349
-
-
- HY-140098
-
-
- HY-129353
-
-
- HY-126496
-
-
- HY-129367
-
-
- HY-118759
-
-
- HY-42973
-
-
- HY-133550
-
-
- HY-19318B
-
-
- HY-79584
-
-
- HY-126405
-
|
SMPT
|
ADC Linker
|
Cancer
|
|
SMPT is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-129352
-
-
- HY-133542
-
-
- HY-U00265
-
|
3-CPs
3-Carbethoxypsoralen; 3-Ethoxycarbonylpsoralen
|
Others
|
Infection
|
|
3-CPs is a serotype capsular polysaccharide which can interfere with antibody-mediated bacterial killing.
|
-
- HY-126531
-
-
- HY-136104
-
-
- HY-W000423
-
-
- HY-W071006
-
|
PPC-NHS ester
2,5-Dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate
|
ADC Linker
|
Cancer
|
|
PPC-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-133543
-
-
- HY-20560
-
-
- HY-114697
-
-
- HY-122872
-
|
MKK7-COV-9
|
p38 MAPK
|
Cancer
|
|
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.
|
-
- HY-15579B
-
|
MMAF sodium
Monomethylauristatin F sodium
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
|
-
- HY-15579
-
|
MMAF
Monomethylauristatin F
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A.
|
-
- HY-111012
-
-
- HY-12693
-
|
R(+)-IAA-94
R(+)-Methylindazone
|
Chloride Channel
|
Others
|
|
R(+)-IAA-94 (R(+)-Methylindazone) is a potent indanyloxyacetic acid blocker of epithelial chloride channels. R(+)-IAA-94 inhibits Nef-sdAb19 (single-domain antibody) interaction and binds to negative factor (Nef).
|
-
- HY-136033
-
-
- HY-140987
-
-
- HY-140313
-
-
- HY-130110
-
-
- HY-140306
-
-
- HY-W019543
-
-
- HY-23641
-
-
- HY-140105
-
-
- HY-141158
-
-
- HY-136031
-
-
- HY-140100
-
-
- HY-140296
-
-
- HY-D0799
-
-
- HY-138327
-
-
- HY-130099
-
-
- HY-135973
-
-
- HY-136032
-
-
- HY-135978
-
-
- HY-135972
-
-
- HY-41189
-
-
- HY-140096
-
-
- HY-126851
-
-
- HY-126518
-
-
- HY-W096127
-
-
- HY-130928
-
-
- HY-116063
-
-
- HY-128929
-
-
- HY-44221
-
-
- HY-140122
-
-
- HY-135418
-
-
- HY-123687
-
-
- HY-140104
-
-
- HY-19318C
-
-
- HY-138506
-
-
- HY-129360
-
-
- HY-126517
-
-
- HY-135977
-
-
- HY-131084
-
-
- HY-132162
-
-
- HY-W011541
-
-
- HY-W002213
-
-
- HY-140129
-
-
- HY-136039
-
-
- HY-79129
-
-
- HY-126686
-
-
- HY-136138
-
-
- HY-130112
-
-
- HY-124329
-
-
- HY-130935
-
-
- HY-101153
-
-
- HY-126364
-
-
- HY-140138
-
-
- HY-20336
-
|
Mc-Val-Cit-PABC-PNP
Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate
|
ADC Linker
|
Cancer
|
|
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-136102
-
-
- HY-140102
-
-
- HY-W023121
-
-
- HY-141141
-
-
- HY-117409
-
-
- HY-126524
-
-
- HY-140140
-
-
- HY-130810
-
-
- HY-138322
-
-
- HY-129362
-
-
- HY-138387
-
-
- HY-129349
-
-
- HY-78738
-
-
- HY-W038702
-
-
- HY-133504
-
-
- HY-114430
-
-
- HY-128527
-
|
PROTAC ER Degrader-3
|
PROTAC
Estrogen Receptor/ERR
|
Cancer
|
|
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
|
-
- HY-131057
-
-
- HY-130989
-
-
- HY-N8395
-
|
Tunicamycin V
Tunicamycin A
|
Bacterial
|
Infection
|
|
Tunicamycin V (Tunicamycin A) is a nucleoside natural product that inhibits bacterial phospho-N-acetylmuramyl-pentapeptide transferase (MraY) with an IC50 of 0.35 μM. Tunicamycin V has antibacterial activties.
|
-
- HY-15295
-
|
Vonoprazan Fumarate
TAK-438
|
Proton Pump
|
Metabolic Disease
|
|
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.
|
-
- HY-130956
-
-
- HY-126353
-
-
- HY-44234
-
-
- HY-130089
-
-
- HY-130090
-
-
- HY-140116
-
-
- HY-124329A
-
-
- HY-130937
-
-
- HY-133412
-
-
- HY-130961
-
-
- HY-130936
-
-
- HY-141145
-
-
- HY-44222
-
-
- HY-130932
-
-
- HY-136136
-
-
- HY-140118
-
-
- HY-133413
-
-
- HY-126533
-
-
- HY-131833
-
-
- HY-141144
-
-
- HY-126513
-
-
- HY-126670
-
-
- HY-141142
-
-
- HY-130098
-
-
- HY-140117
-
-
- HY-130930
-
-
- HY-130088
-
-
- HY-140120
-
-
- HY-140125
-
-
- HY-126497
-
-
- HY-126516
-
-
- HY-136107
-
-
- HY-126663
-
-
- HY-130087
-
-
- HY-135975
-
-
- HY-130086
-
-
- HY-W071007
-
-
- HY-100007
-
|
Vonoprazan
TAK-438 free base
|
Proton Pump
|
Endocrinology
|
|
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.
|
-
- HY-W040236
-
-
- HY-133547
-
-
- HY-129356A
-
-
- HY-129351
-
-
- HY-133548
-
-
- HY-78921
-
-
- HY-130976
-
-
- HY-136132
-
-
- HY-129350
-
-
- HY-130547
-
-
- HY-129378
-
-
- HY-136125
-
-
- HY-133549
-
-
- HY-138521
-
-
- HY-130975
-
-
- HY-140119
-
-
- HY-120770
-
-
- HY-W011561
-
-
- HY-130933
-
-
- HY-138535
-
-
- HY-126502
-
-
- HY-136329
-
-
- HY-112099
-
|
Mc-Val-Cit-PAB-Cl
|
ADC Linker
|
Cancer
|
|
Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE with IC50s of 3.3 and 0.95 nM for BJAB and WSU cell lines in cytotoxicity assay).
|
-
- HY-136170
-
|
MC-SN38
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-SN38 is a drug-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody drug conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks.
|
-
- HY-P9926
-
-
- HY-112616
-
|
NAMPT inhibitor-linker 2
|
NAMPT
Drug-Linker Conjugates for ADC
|
Cancer
|
|
NAMPT inhibitor-linker 2 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC50s of <7 pM and 40 pM, respectively.
|
-
- HY-126523
-
-
- HY-136154
-
-
- HY-126521
-
-
- HY-141143
-
-
- HY-126495A
-
-
- HY-130097
-
-
- HY-126522
-
-
- HY-133584
-
-
- HY-126520
-
-
- HY-140126
-
-
- HY-126690
-
-
- HY-15486
-
|
Salubrinal
|
Phosphatase
HSV
Autophagy
Apoptosis
|
Cancer
Infection
Inflammation/Immunology
|
|
Salubrinal is a cell-permeable and selective inhibitor of eIF2α dephosphorylation. Salubrinal acts as a dual-specificity phosphatase 2 (Dusp2) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. Salubrinal has antiviral activity against HSV-1 and inhibits dephosphorylation of eIF2α mediated by the HSV-1 protein ICP34.5.
|
-
- HY-112615
-
|
NAMPT inhibitor-linker 1
|
NAMPT
Drug-Linker Conjugates for ADC
|
Cancer
|
|
NAMPT inhibitor-linker 1 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC50s of <3 pM and 9 pM, respectively.
|
-
- HY-141355
-
-
- HY-136287
-
-
- HY-131086
-
-
- HY-126883
-
-
- HY-136106
-
-
- HY-W040254
-
|
Biotin-LC-LC-NHS
|
Others
|
Others
|
|
Biotin-LC-LC-NHS is a SMCC cross-linking reagent that can be used to mark antibody and other small molecules, such as Paclitaxel.
|
-
- HY-136432
-
-
- HY-141123
-
-
- HY-133408
-
-
- HY-126525
-
-
- HY-129311
-
-
- HY-133585
-
-
- HY-120258
-
-
- HY-115374
-
-
- HY-141353
-
-
- HY-135971
-
-
- HY-W019793
-
-
- HY-128946
-
|
CL2A-SN-38
|
Drug-Linker Conjugates for ADC
|
Cancer
Inflammation/Immunology
|
|
CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a nonclaevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond.
|
-
- HY-136051
-
-
- HY-P1449
-
|
Boc-Gly-Gly-Phe-Gly-OH
|
ADC Linker
|
Cancer
|
|
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
-
- HY-136099
-
-
- HY-136044
-
-
- HY-136309
-
-
- HY-140115
-
-
- HY-136091
-
-
- HY-136052
-
-
- HY-138484
-
-
- HY-135961
-
-
- HY-136086
-
-
- HY-136049
-
-
- HY-116655
-
-
- HY-W096133
-
-
- HY-135974
-
-
- HY-135125
-
|
DC4
|
ADC Cytotoxin
|
Cancer
|
|
DC4, a ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC4 can be used for the targeted treatment of cancer.
|
-
- HY-140244
-
-
- HY-136046
-
-
- HY-140097
-
-
- HY-136045
-
-
- HY-136067
-
-
- HY-136048
-
-
- HY-136127
-
-
- HY-138488
-
-
- HY-136077
-
-
- HY-136061
-
-
- HY-135964
-
-
- HY-136050
-
-
- HY-136075
-
-
- HY-136047
-
-
- HY-136101
-
-
- HY-136074
-
-
- HY-141358
-
-
- HY-130939
-
-
- HY-132163
-
-
- HY-136053
-
-
- HY-130977
-
-
- HY-140352
-
-
- HY-136038
-
-
- HY-132086
-
-
- HY-136056
-
-
- HY-128870
-
-
- HY-130925
-
|
BCN-PEG4-OH
|
ADC Linker
|
Cancer
|
|
BCN-PEG4-OH is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-133433
-
-
- HY-140078
-
-
- HY-133431
-
-
- HY-135962
-
-
- HY-140124
-
-
- HY-130924
-
-
- HY-135966
-
-
- HY-130926
-
-
- HY-136041
-
-
- HY-140130
-
-
- HY-140123
-
-
- HY-130927
-
|
BCN-PEG4-Ts
|
ADC Linker
|
Cancer
|
|
BCN-PEG4-Ts is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-133466
-
-
- HY-140108
-
-
- HY-136035
-
-
- HY-133434
-
-
- HY-133428
-
-
- HY-P1449A
-
-
- HY-136096
-
-
- HY-133430
-
-
- HY-112561
-
-
- HY-130955
-
-
- HY-140134
-
-
- HY-140152
-
-
- HY-136078
-
-
- HY-133432
-
-
- HY-130945
-
-
- HY-130972
-
-
- HY-136087
-
-
- HY-136079
-
-
- HY-140139
-
-
- HY-136040
-
-
- HY-136085
-
-
- HY-136097
-
-
- HY-140930
-
-
- HY-136036
-
-
- HY-133427
-
-
- HY-133429
-
-
- HY-136037
-
-
- HY-140944
-
-
- HY-140132
-
-
- HY-130947
-
-
- HY-138508
-
-
- HY-140136
-
-
- HY-135979
-
-
- HY-136314
-
|
DBCO-PEG4-VC-PAB-MMAE
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). MMAE is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization.
|
-
- HY-122534
-
|
Mensacarcin
|
Mitochondrial Metabolism
ADC Cytotoxin
Apoptosis
|
Cancer
|
|
Mensacarcin, a highly complex polyketide, strongly inhibits cell growth universally in cancer cell lines and potently induces apoptosis in melanoma cells. Mensacarcin targets to mitochondria, affects energy metabolism in mitochondria, and activates caspase-dependent apoptotic pathways. Mensacarcin, an antibiotic, can be used as a cytotoxic component of antibody-drug conjugates (ADCs).
|
-
- HY-130934
-
-
- HY-140309
-
-
- HY-141190
-
-
- HY-141292
-
-
- HY-130103
-
-
- HY-130106
-
-
- HY-136134
-
-
- HY-130104
-
-
- HY-136034
-
-
- HY-W096135
-
-
- HY-126510
-
-
- HY-136135
-
-
- HY-133544
-
-
- HY-130940
-
-
- HY-128930
-
-
- HY-130922
-
-
- HY-140127
-
-
- HY-130094
-
-
- HY-140099
-
-
- HY-141284
-
-
- HY-133435
-
-
- HY-130105
-
-
- HY-130095
-
-
- HY-133538
-
-
- HY-136141
-
-
- HY-130101
-
-
- HY-130092
-
-
- HY-130093
-
-
- HY-133459
-
-
- HY-130962
-
-
- HY-130954
-
-
- HY-130941
-
-
- HY-140145
-
-
- HY-136137
-
-
- HY-140148
-
-
- HY-133576
-
-
- HY-133575
-
-
- HY-141150
-
-
- HY-133545
-
-
- HY-136100
-
-
- HY-136108
-
-
- HY-141149
-
-
- HY-141156
-
-
- HY-136157
-
-
- HY-133426
-
-
- HY-P3149B
-
|
LEESGGGLVQPGGSMK acetate
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-140113
-
-
- HY-130966
-
-
- HY-130091
-
-
- HY-136155
-
-
- HY-136098
-
-
- HY-136054
-
-
- HY-140143
-
-
- HY-112901
-
|
DC41
|
ADC Cytotoxin
|
Cancer
|
|
DC41 is a DC1 derivative. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.
|
-
- HY-141154
-
-
- HY-131082
-
-
- HY-131087
-
-
- HY-P3149
-
|
LEESGGGLVQPGGSMK
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-140112
-
-
- HY-130944
-
-
- HY-136286
-
-
- HY-133436
-
-
- HY-133573
-
-
- HY-133579
-
-
- HY-126669
-
|
Mal-PEG4-VA
|
ADC Linker
|
Cancer
|
|
Mal-PEG4-VA is a cleavable ADC linker containing a Maleimide group. Mal-PEG4-VA is used for making antibody-drug conjugate.
|
-
- HY-136103
-
-
- HY-133409
-
-
- HY-136105
-
-
- HY-130923
-
-
- HY-141155
-
-
- HY-141151
-
-
- HY-112899
-
-
- HY-140147
-
-
- HY-141146
-
-
- HY-133572
-
-
- HY-140146
-
-
- HY-128873
-
-
- HY-107770
-
-
- HY-115524
-
|
DBCO-NHS ester 2
|
ADC Linker
|
Cancer
|
|
DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry.
|
-
- HY-132159
-
-
- HY-130315
-
-
- HY-W096148
-
-
- HY-18987
-
-
- HY-140109
-
-
- HY-136076
-
-
- HY-136131
-
-
- HY-130990
-
-
- HY-101157
-
|
Propargyl-PEG5-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-acid can used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-114816
-
|
N-Butanoyl-L-homoserine lactone
C4-HSL; N-Butyryl-L-homoserine lactone
|
ADC Linker
Bacterial
|
Infection
Inflammation/Immunology
|
|
N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa.
|
-
- HY-136133
-
-
- HY-140121
-
-
- HY-136058
-
-
- HY-126529
-
-
- HY-135970
-
-
- HY-130968
-
-
- HY-136088
-
-
- HY-133581
-
-
- HY-130973
-
-
- HY-P3149A
-
|
LEESGGGLVQPGGSMK TFA
|
TNF Receptor
|
Inflammation/Immunology
|
|
LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
|
-
- HY-130108
-
-
- HY-130971
-
-
- HY-130943
-
-
- HY-140111
-
-
- HY-130970
-
-
- HY-126527
-
-
- HY-129526
-
|
Mal-PEG3-NHS ester
|
ADC Linker
|
Cancer
|
|
Mal-PEG3-NHS ester is a noncleavable ADC linker containing a Maleimide group. Mal-PEG3-NHS ester is used for making antibody-drug conjugate.
|
-
- HY-P1787
-
-
- HY-130953
-
-
- HY-136089
-
-
- HY-140110
-
-
- HY-126528
-
-
- HY-126526
-
-
- HY-140634
-
-
- HY-140133
-
-
- HY-136060
-
-
- HY-136318
-
-
- HY-130109
-
-
- HY-101150
-
|
DGN462
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs).
|
-
- HY-W040135
-
-
- HY-128880
-
-
- HY-133574
-
-
- HY-126514
-
-
- HY-130929
-
-
- HY-130817
-
|
Mc-O-Si(di-iso)-Cl
|
ADC Linker
|
Cancer
|
|
Mc-O-Si(di-iso)-Cl is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812) ).
|
-
- HY-W040246
-
-
- HY-128881
-
-
- HY-130967
-
-
- HY-130974
-
-
- HY-141091
-
-
- HY-130931
-
-
- HY-133539
-
-
- HY-126515
-
-
- HY-133582
-
-
- HY-W044078
-
|
N-Boc-diethanolamine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-diethanolamine is an Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-diethanolamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130546
-
-
- HY-130818
-
-
- HY-130978
-
|
Duocarmycin DM
|
DNA Alkylator/Crosslinker
ADC Cytotoxin
|
Cancer
|
|
Duocarmycin DM, a DNA minor-groove alkylator, is an antibody drug conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity.
|
-
- HY-117050
-
|
PEG12-Tos
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Tos-PEG12 is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). PEG12-Tos is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-44149
-
-
- HY-121805
-
|
DBCO-C6-acid
|
ADC Linker
|
Cancer
|
|
DBCO-C6-acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). DBCO-C6-acid can be used in the synthesis of carmaphycin analogues.
|
-
- HY-136090
-
-
- HY-131990
-
-
- HY-W007324
-
|
Maleimide
|
Others
|
Cancer
|
|
Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes.
|
-
- HY-140101
-
-
- HY-101070
-
-
- HY-41541
-
|
Tetraethylene glycol monotosylate
Tos-PEG4
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Tetraethylene glycol monotosylate is a cleavable and acylhydrazone-based ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Tetraethylene glycol monotosylate also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130957
-
-
- HY-130969
-
-
- HY-126671
-
-
- HY-133546
-
-
- HY-140242
-
-
- HY-136084
-
-
- HY-136130
-
-
- HY-126894
-
|
Bis-PEG9-acid
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG9-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG9-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126893
-
|
Bis-PEG8-acid
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG8-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126886
-
|
Mal-PEG1-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Mal-PEG1-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG1-NHS ester is PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130383
-
|
Propargyl-PEG7-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG7-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG7-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130386
-
|
Propargyl-PEG6-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG6-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126892
-
|
Bis-PEG7-acid
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG7-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG6-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126668
-
|
Mal-PEG4-VC-PAB-DMEA
|
ADC Linker
|
Cancer
|
|
Mal-PEG4-VC-PAB-DMEA is a cleavable ADC linker containing a Maleimide group. Mal-PEG4-VC-PAB-DMEA is used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-42745
-
|
m-PEG2-Tos
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG2-Tos is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG2-Tos is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130166
-
|
Amino-PEG9-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG9-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Amino-PEG9-acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126672
-
|
Mal-PEG4-Val-Cit-PAB
|
ADC Linker
|
Cancer
|
|
Mal-PEG4-Val-Cit-PAB is a cleavable ADC linker containing a Maleimide group. Mal-PEG4-Val-Cit-PAB is used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126958
-
-
- HY-126674
-
-
- HY-130528
-
|
m-PEG7-Ms
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG7-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG7-Ms is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-141170
-
|
TCO-PEG12-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
TCO-PEG12-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. TCO-PEG12-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130408
-
|
m-PEG6-Amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG6-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG6-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130457
-
|
m-PEG4-Ms
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG4-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG4-Ms is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W018174
-
|
m-PEG3-Amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG3-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG3-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-120237
-
|
m-PEG7-Amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG7-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG7-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130346
-
|
DBCO-PEG4-DBCO
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
DBCO-PEG4-DBCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-PEG4-DBCO is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-141167
-
|
TCO-PEG4-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
TCO-PEG4-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. TCO-PEG4-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-116186
-
|
m-PEG5-Ms
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG5-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG5-Ms is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W040214
-
|
m-PEG4-Amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG4-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG4-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130475
-
-
- HY-118808
-
|
Propargyl-PEG2-NHBoc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG2-NHBoc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-NHBoc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
|
-
- HY-126673
-
|
Mal-C2-Gly3-EDA
|
ADC Linker
|
Cancer
|
|
Mal-C2-Gly3-EDA is a cleavable ADC linker containing a Maleimide group. Mal-C2-Gly3-EDA is used for making antibody-drug conjugate.
|
-
- HY-136297
-
|
DGN549-C
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-117519
-
-
- HY-W008429
-
|
m-PEG2-Amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG2-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG2-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-131833A
-
|
Fmoc-Gly-Gly-D-Phe-OH
|
ADC Linker
|
Cancer
|
|
Fmoc-Gly-Gly-D-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Gly-Gly-D-Phe-OH is the D-isomer of Fmoc-Gly-Gly-Phe-OH (HY-131833).
|
-
- HY-140310
-
|
TCO-PEG4-DBCO
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
TCO-PEG4-DBCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. TCO-PEG4-DBCO is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-133583
-
-
- HY-141379
-
|
N-Bromoacetyl-β-alanine
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
N-Bromoacetyl-β-alanine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. N-Bromoacetyl-β-alanine is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-128915
-
-
- HY-130571
-
|
m-PEG9-Amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG9-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG9-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126960
-
-
- HY-125541
-
|
DBCO-NHCO-PEG4-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
DBCO-Amide-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-Amide-PEG5-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-117031
-
|
m-PEG8-Ms
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG8-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG8-Ms is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130410
-
|
Bis-PEG6-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Bis-PEG6-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG6-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-116427
-
|
Propargyl-PEG4-thiol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG4-thiol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-thiol is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130328
-
|
NH-bis-PEG2
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
NH-bis-PEG2 is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH-bis-PEG2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130372
-
|
Propargyl-PEG9-bromide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG9-bromide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG9-bromide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130387
-
|
Propargyl-PEG4-Tos
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Propargyl-PEG4-Tos is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-Tos is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W040222
-
|
m-PEG11-Amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG11-Amino is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG11-Amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-136129
-
-
- HY-130591
-
|
Propargyl-PEG4-Br
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG4-Br is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-Br is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126976
-
|
Propargyl-PEG5-amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG5-amine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
|
-
- HY-130377
-
|
Propargyl-PEG8-bromide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG8-bromide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-bromide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-44234A
-
|
Fmoc-Gly-Gly-D-Phe-OtBu
|
ADC Linker
|
Cancer
|
|
Fmoc-Gly-Gly-D-Phe-OtBu is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Gly-Gly-D-Phe-OtBu is the R-isomer of Fmoc-Gly-Gly-Phe-OtBu (HY-44234).
|
-
- HY-126974
-
|
Propargyl-PEG3-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG3-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG3-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130165
-
-
- HY-120845
-
-
- HY-130388
-
|
Propargyl-PEG5-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG5-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG5-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-117009
-
|
Bis-PEG9-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Bis-PEG9-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG9-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126889
-
|
Bis-PEG5-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Bis-PEG5-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG5-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-115545
-
|
DBCO-NHS ester 3
|
ADC Linker
|
Cancer
|
|
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC).
|
-
- HY-130825
-
|
Bis-PEG13-NHS ester
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG13-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG13-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130381
-
|
Propargyl-PEG7-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG7-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG7-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130827
-
|
Bis-PEG21-NHS ester
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG21-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG21-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-100216
-
|
SPDP
SPDP Crosslinker
|
ADC Linker
|
Cancer
|
|
SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs).
|
-
- HY-130385
-
|
Propargyl-PEG6-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG6-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG6-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130826
-
|
Bis-PEG17-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Bis-PEG17-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG17-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130828
-
|
Bis-PEG25-NHS ester
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG25-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG25-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W051634
-
|
Propargyl-PEG2-amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG2-amine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
|
-
- HY-130376
-
|
Propargyl-PEG8-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG8-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126890
-
|
Bis-PEG7-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Bis-PEG7-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG7-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130824
-
|
Bis-PEG10-NHS ester
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG10-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG10-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-118764
-
|
Propargyl-PEG2-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG2-acid is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-126885
-
|
DBCO-PEG5-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
DBCO-PEG5-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-PEG5-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-140454
-
|
Azido-PEG8-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG8-acid is a non-cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG8-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-117104
-
|
Hydroxy-PEG4-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Hydroxy-PEG4-acid is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-141385
-
|
N-Succinimidyl 3-(Bromoacetamido)propionate
3-(2-Bromoacetamido)propanoic acid NHS ester
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
N-Succinimidyl 3-(Bromoacetamido)propionate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. N-Succinimidyl 3-(Bromoacetamido)propionate is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-120702
-
|
N-Boc-PEG5-bromide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-PEG5-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG5-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W006445
-
|
N-Boc-PEG3-bromide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-PEG3-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG3-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-111456
-
|
DBCO-NHCO-PEG4-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
DBCO-NHCO-PEG4-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130505
-
|
N-Boc-PEG7-alcohol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-PEG7-alcohol is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG7-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W071584
-
|
N-Boc-PEG6-alcohol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-PEG6-alcohol is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG6-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W019799
-
|
Amino-PEG8-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG8-Boc is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG8-Boc is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-141382
-
|
Bromoacetamido-PEG4-acid
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bromoacetamido-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Bromoacetamido-PEG4-acid is also a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W046471
-
|
N-Boc-PEG4-bromide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-PEG4-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG4-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130503
-
|
N-Boc-PEG2-bromide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-PEG2-bromide is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG2-bromide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-133066
-
-
- HY-W071583
-
|
N-Boc-PEG9-alcohol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-PEG9-alcohol is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-PEG9-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-128945
-
|
CL2A
|
ADC Linker
|
Cancer
Inflammation/Immunology
|
|
CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker.
|
-
- HY-113764
-
|
N-Butanoyl-DL-homoserine lactone
(Rac)-C4-HSL
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
N-Butanoyl-DL-homoserine lactone ((Rac)-C4-HSL) is a racemic mixture of N-Butanoyl-D-homoserine lactone and N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa.
|
-
- HY-140501
-
|
m-PEG11-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG11-acid is a non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG11-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-126942
-
|
Amino-PEG6-alcohol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG6-alcohol is a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG6-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130324
-
|
Azido-PEG7-amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG7-amine is a non-cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG7-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130298
-
|
Amino-PEG11-OH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG11-OH is non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG11-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-140500
-
|
m-PEG10-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG10-acid is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130169
-
|
Azido-PEG9-amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG9-amine is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG9-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-120761
-
|
Amino-PEG10-OH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG10-OH is non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG10-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-120944
-
|
BAY-7598
|
MMP
|
Inflammation/Immunology
|
|
BAY-7598 is a potent, orally bioavailable, and selective MMP12 inhibitor probe with IC50s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively.
|
-
- HY-130449
-
|
N-Boc-N-bis(PEG4-OH)
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-N-bis(PEG4-OH) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-N-bis(PEG4-OH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-141395
-
|
m-PEG4-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG4-Boc is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG4-Boc is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-21577
-
-
- HY-126884
-
|
DBCO-NHCO-PEG4-NH-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
DBCO-NHCO-PEG4-NH-Boc is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-NH-Boc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-W042654
-
-
- HY-140811
-
|
Azido-PEG3-maleimide
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Azido-PEG3-maleimide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG3-maleimide is also a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126676
-
-
- HY-130150
-
-
- HY-140215
-
|
Azido-PEG6-amine
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Azido-PEG6-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG6-amine is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126918
-
|
THP-PEG6-OH
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
THP-PEG6-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. THP-PEG6-OH is also a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-140226
-
|
m-PEG10-amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG10-amine is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-126951
-
|
Aminooxy-PEG2-alcohol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Aminooxy-PEG2-alcohol is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Aminooxy-PEG2-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-140004
-
|
Azide-PEG3-Tos
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Azide-PEG3-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azide-PEG3-Tos is also a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-113931
-
|
Aminooxy-PEG2-azide
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Aminooxy-PEG2-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Aminooxy-PEG2-azide is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130537
-
|
Azido-PEG6-alcohol
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Azido-PEG6-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG6-alcohol is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130211
-
|
Azido-PEG5-alcohol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG5-alcohol is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG5-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-141220
-
|
m-PEG12-OH
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
m-PEG12-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. m-PEG12-OH is also a non-cleavable 12 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130946
-
-
- HY-130222
-
-
- HY-140227
-
|
m-PEG12-amine
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
m-PEG12-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. m-PEG12-amine is also a non-cleavable 12 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-124123
-
|
Aminooxy-PEG4-alcohol
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Aminooxy-PEG4-alcohol is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Aminooxy-PEG4-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-B0245S
-
|
Busulfan-D8
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
Busulfan-D8 is a deuterium labeled Busulfan. Busulfan is an alkyl sulfonate that acts as an alkylating antineoplastic agent. Busulfan forms both intra- and interstrand crosslinks on DNA. In mammals, Busulfan causes profound and prolonged reduction in the generation of hematopoietic progenitors without significantly affecting lymphocyte levels or humoral antibody responses.
|
-
- HY-W008005
-
|
Amino-PEG4-alcohol
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Amino-PEG4-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Amino-PEG4-alcohol is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-114995
-
-
- HY-130379
-
|
Propargyl-PEG8-acid
|
ADC Linker
PROTAC Linker
Bacterial
|
Cancer
Infection
|
|
Propargyl-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). The ADCs can be used in bacterial infections caused by Gram-negative bacteria.
|
-
- HY-115384
-
|
Amino-PEG5-C2-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG5-C2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Amino-PEG5-C2-acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130474
-
|
Azido-PEG6-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG6-NHS ester is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG6-NHS ester is also a PEG- and Alkyl/ether based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130182
-
|
Propargyl-PEG8-NH2
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Propargyl-PEG8-NH2 (compound 3b) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-NH2 is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-120775
-
-
- HY-W040165
-
|
Amino-PEG3-C2-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG3-C2-acid is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG3-C2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-140151
-
|
BCN-PEG3-Val-Cit
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
BCN-PEG3-Val-Cit is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. BCN-PEG3-Val-Cit is also a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130184
-
|
Azido-PEG8-NHS ester
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG8-NHS ester is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG8-NHS ester is also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-117079
-
|
N-Boc-N-bis(PEG2-OH)
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N-Boc-N-bis(PEG2-OH) is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. N-Boc-N-bis(PEG2-OH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-112560
-
|
Bis-PEG2-PFP ester
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Bis-PEG2-PFP ester is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Bis-PEG2-PFP ester is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130485
-
|
Bromo-PEG2-C2-azide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Bromo-PEG2-C2-azide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Bromo-PEG2-C2-azide is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W040168
-
|
Amino-PEG2-C2-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Amino-PEG2-C2-acid is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG2-C2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-140081
-
|
Boc-gly-PEG3-endo-BCN
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Boc-gly-PEG3-endo-BCN is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Boc-gly-PEG3-endo-BCN is also a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-120537
-
|
m-PEG5-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG5-CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG5-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-140150
-
|
Azido-PEG3-Val-Cit-PAB-PNP
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-140149
-
|
Azido-PEG4-Val-Cit-PAB-OH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-126949
-
|
Aminooxy-PEG3-azide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Aminooxy-PEG3-azide is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Aminooxy-C2-PEG3-azide is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-112900
-
|
DC41SMe
|
ADC Cytotoxin
|
Cancer
|
|
DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC50s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.
|
-
- HY-42640
-
|
Boc-NH-PEG4-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Boc-NH-PEG4-CH2COOH is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC). Boc-NH-PEG4-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130144
-
|
Ald-CH2-PEG3-azide
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Ald-CH2-PEG3-azide is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Ald-CH2-PEG3-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
|
-
- HY-141218
-
|
m-PEG10-alcohol
Decaethylene glycol monomethyl ether
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG10-alcohol (Decaethylene glycol monomethyl ether) is a non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130653
-
-
- HY-133062
-
|
Fmoc-NH-PEG5-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG5-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG5-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130572
-
-
- HY-130364
-
|
Fmoc-NH-PEG6-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG6-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG6-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W019798
-
|
NH2-PEG9-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
NH2-PEG9-acid is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG9-acid also is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-133063
-
|
Fmoc-NH-PEG8-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG8-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG8-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W055861
-
|
Fmoc-NH-PEG1-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG1-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG1-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130175
-
|
Fmoc-NH-PEG4-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG4-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG4-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130486
-
|
NH2-PEG6-Boc
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
NH2-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG6-Boc is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-130442
-
|
Mal-PEG2-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Mal-PEG2-acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-acid can be conjugated to Tubulysin (HY-128914) and its derivative cytotoxic molecule. Mal-PEG2-acid is also a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-129637
-
|
NH2-PEG5-OH
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
NH2-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG5-OH is also a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-126493
-
|
DM4-SPDP
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
DM4-SPDP is a drug-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody drug conjugate. SPDP is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls.
|
-
- HY-P1439
-
|
RS 09
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
RS 09 is a TLR4 agonist. RS 09 promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro. RS 09 acts as an adjuvant in vivo; RS 09 enhances X-15 specific antibody serum concentrations, when administered with X-15-KLH in mice.
|
-
- HY-130524
-
|
Amino-PEG4-CH2COOH
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Amino-PEG4-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Amino-PEG4-CH2COOH is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-132161
-
-
- HY-130185
-
|
m-PEG7-CH2CH2CHO
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG7-CH2CH2CHO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG7-CH2CH2CHO is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W067509
-
|
m-PEG3-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG3-CH2CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-42618
-
|
Azido-PEG4-CH2-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG4-CH2-Boc is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-CH2-Boc is also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W035376
-
|
m-PEG6-CH2CH2CHO
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG6-CH2CH2CHO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG6-CH2CH2CHO is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-109714
-
|
3,4-Benzocoumarin
|
Others
|
Inflammation/Immunology
|
|
3,4-Benzocoumarin is a kind of the expanded structure of coumarin derivatives.Coumarin is a chemical compound in the benzopyrone chemical class that can be found in many natural species. Coumarins possess variety of biological activities and unique photophysical properties. 3,4-Benzocoumarin, a AOH‐like compound , has the sensibility of the antibody with an IC50 of 919.2 ng/mL.
|
-
- HY-130151
-
|
m-PEG7-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG7-CH2CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG7-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-135124
-
|
DC44SMe
|
ADC Cytotoxin
|
Cancer
|
|
DC44SMe, a phosphate prodrug of cytotoxic DNA alkylator DC44, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC44SMe exhibits IC50s of 2.0 nM, 2.8 nM, and 1.9 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC44SMe can be used for the targeted treatment of cancer.
|
-
- HY-135123
-
|
DC4SMe
|
ADC Cytotoxin
|
Cancer
|
|
DC4SMe, a phosphate prodrug of cytotoxic DNA alkylator DC4, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC4SMe exhibits IC50s of 1.9 nM, 2.9 nM, and 1.8 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC4SMe can be used for the targeted treatment of cancer.
|
-
- HY-129937A
-
|
GNE-987
|
PROTAC
Epigenetic Reader Domain
|
Cancer
|
|
GNE-987 is a highly active chimeric BET degrader. GNE-987 exhibits picomolar cell BRD4 degradation activity (DC50=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50=4.7 and 4.4 nM, respectively). GNE-987 incorporates a potent BET binder/inhibitor, a VHL-binding fragment, and a ten methylene spacer moiety. GNE-987 can be used in PROTAC-Antibody Conjugate (PAC).
|
-
- HY-130167
-
|
Fmoc-NH-PEG9-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG9-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG9-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130690
-
-
- HY-W040238
-
|
Fmoc-NH-PEG2-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG2-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG2-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130194
-
|
Azido-PEG5-CH2CO2H
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Azido-PEG5-CH2CO2H is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG5-CH2CO2H is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W007713
-
|
Fmoc-8-amino-3,6-dioxaoctanoic acid
Fmoc-NH-PEG2-CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-NH-PEG2-CH2COOH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-8-amino-3,6-dioxaoctanoic acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-129942
-
|
S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate
|
ADC Linker
|
Cancer
|
|
S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs) and refers to the Alkyl-Chain composition. S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is the linker portions of the molecules employed for mAb attachment purposes.
|
-
- HY-124386
-
|
DBCO-NHCO-PEG4-amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
DBCO-NHCO-PEG4-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-amine is a cleavable ADC linker used to conjugate MMAE (HY-15162) and antibody (e.g., DBCO-VCpAB−MMAE and DBCO-TRX−MMAE with EC50s of 280 nM and 22 nM in SKBR3 cells, respectively).
|
-
- HY-130435
-
|
DBCO-PEG4-amine
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
DBCO-PEG4-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-PEG4-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). DBCO-PEG4-amine can be used in the synthesis of FPM-PEG4-DBCO (a homobifunctional azide-to-azide cross-linker).
|
-
- HY-W040231
-
|
Fmoc-NH-PEG3-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG3-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W040244
-
|
Boc-NH-PEG6-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Boc-NH-PEG6-CH2CH2COOH is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC). Boc-NH-PEG6-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W000434
-
|
Fmoc-NH-PEG4-CH2CH2COOH
Fmoc-15-amino-4,7,10,13-tetraoxapentadecanoic acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Fmoc-NH-PEG4-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG4-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W035378
-
-
- HY-W040132
-
-
- HY-42149
-
|
NH2-PEG2-C2-Boc
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
NH2-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG2-C2-Boc is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-112898
-
|
DC1SMe
|
ADC Cytotoxin
|
Cancer
|
|
DC1Sme, a DC1 derivative, exhibits IC50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.
|
-
- HY-130426
-
|
Maleimido-tri(ethylene glycol)-propionic acid
Mal-PEG3-acid
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-specific cysteine mutant trastuzumab-A114C conjugation. Maleimido-tri(ethylene glycol)-propionic acid also can be used as a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-42490
-
-
- HY-W021787
-
|
NH2-PEG4-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
NH2-PEG4-CH2CH2COOH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG4-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-130161
-
|
m-PEG4-Br
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency. m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-126677
-
-
- HY-W039178
-
|
Hydroxy-PEG4-(CH2)2-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Hydroxy-PEG4-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 191). Hydroxy-PEG4-(CH2)2-Boc is also a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W008352
-
|
Boc-NH-PEG4-CH2CH2NH2
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Boc-NH-PEG4-CH2CH2NH2 a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-NH-PEG4-CH2CH2NH2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-42488
-
|
Hydroxy-PEG3-(CH2)2-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196). Hydroxy-PEG2-(CH2)2-Boc is also a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W040257
-
|
NH2-PEG6-CH2CH2COOH
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
NH2-PEG6-CH2CH2COOH is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG6-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W067061
-
|
Hydroxy-PEG2-(CH2)2-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196). Hydroxy-PEG2-(CH2)2-Boc is also a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-42489
-
|
N3-PEG3-CH2CH2-Boc
|
ADC Linker
PROTAC Linker
|
Cancer
|
|
N3-PEG3-CH2CH2-Boc is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N3-PEG3-CH2CH2-Boc is also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-132160
-
|
7-Aminomethyl-10-methyl-11-fluoro camptothecin
|
ADC Cytotoxin
|
Cancer
|
|
7-Aminomethyl-10-methyl-11-fluoro camptothecin is a cytotoxin of MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (HY-132158，compound 21a). 7-Aminomethyl-10-methyl-11-fluoro camptothecin can be used for the synthesis of camptothecin antibody-drug conjugate (ADC).
|
-
- HY-140213
-
|
Azido-PEG2-C2-amine
N3-PEG2-CH2CH2NH2
|
PROTAC Linker
ADC Linker
|
Cancer
|
|
Azido-PEG2-C2-amine (N3-PEG2-CH2CH2NH2) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG2-C2-amine is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
- HY-137471
-
|
RBPJ Inhibitor-1
RIN1
|
Notch
|
Cancer
|
|
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation.
|
-
- HY-131344
-
|
mTOR inhibitor-8
|
mTOR
Autophagy
|
Cancer
|
|
mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells.
|
-
- HY-136123
-
|
Tubulin inhibitor 8
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 8 (Compound 33b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 8 inhibits tubulin polymerization with an IC50 of 0.73 μM. Tubulin inhibitor 8 inhibits K562 cell growth with an IC50 of 14 nM.
|
-
- HY-136122
-
|
Tubulin inhibitor 7
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 7 (Compound 33c) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 7 inhibits tubulin polymerization with an IC50 of 0.52 μM. Tubulin inhibitor 7 inhibits K562 cell growth with an IC50 of 11 nM.
|
-
- HY-136121
-
|
Tubulin inhibitor 6
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 6 (Compound 14b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 6 inhibits tubulin polymerization with an IC50 of 0.87 μM. Tubulin inhibitor 6 inhibits K562 cell growth with an IC50 of 840 nM.
|
-
- HY-112851
-
-
- HY-112812
-
-
- HY-18353
-
|
mTOR inhibitor-3
|
mTOR
|
Cancer
|
|
mTOR inhibitor-3 is a remarkably selective mTOR inhibitor with a Ki of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.
|
-
- HY-B0552A
-
-
- HY-112911
-
-
- HY-B0552
-
-
- HY-112722
-
-
- HY-137497
-
|
KRAS inhibitor-9
|
Ras
Apoptosis
|
Cancer
|
|
KRAS inhibitor-9, a potent KRAS inhibitor (Kd=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells.
|
-
- HY-D0843
-
|
N-Ethylmaleimide
NEM
|
Cathepsin
Deubiquitinase
|
Others
|
|
N-Ethylmaleimide (NEM), a reagent that alkylates free sulfhydryl groups, is a cysteine protease inhibitor. N-ethylmaleimide specific inhibits phosphate transport in mitochondria. N-Ethylmaleimide is also a deubiquitinating enzyme inhibitor.
|
-
- HY-101275
-
-
- HY-13278A
-
-
- HY-111370
-
|
mTOR inhibitor-2
|
mTOR
|
Cancer
|
|
mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates.
|
-
- HY-119369
-
-
- HY-111412
-
-
- HY-21141
-
|
Cysteine protease inhibitor-2
|
Cathepsin
|
Cancer
|
|
Cysteine protease inhibitor-2 is a cysteine protease inhibitor extracted from patent US20070032499A1, compound 12. Cysteine protease inhibitor-2 inhibits the cells growth of DCT116 and PC3 cells with GI50 values of 6.5 μM and 4.4 μM, respectively.
|
-
- HY-17541A
-
-
- HY-17541
-
-
- HY-112914
-
-
- HY-70005
-
-
- HY-130260
-
-
- HY-128703
-
-
- HY-10442
-
-
- HY-138295
-
|
KRAS inhibitor-10
|
Ras
|
Cancer
|
|
KRAS inhibitor-10 selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1.
|
-
- HY-12186
-
|
3-Deazaneplanocin A hydrochloride
DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride
|
Histone Methyltransferase
|
Cancer
|
|
3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent histone methyltransferase EZH2 inhibitor. 3-Deazaneplanocin A hydrochlorideis a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor.
|
-
- HY-112807
-
|
SGLT inhibitor-1
|
SGLT
|
Metabolic Disease
|
|
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively.
|
-
- HY-128722
-
-
- HY-110101
-
-
- HY-12202
-
-
- HY-B0543
-
-
- HY-10421
-
-
- HY-B0385
-
-
- HY-32015
-
|
Cot inhibitor-1
|
MAP3K
|
Inflammation/Immunology
|
|
Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC50 of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC50 of 5.7 nM.
|
-
- HY-P0017
-
-
- HY-112843
-
|
CNT2 inhibitor-1
|
Others
|
Others
|
|
CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2.
|
-
- HY-115514A
-
|
BRK inhibitor P21d hydrochloride
|
Others
|
Cancer
|
|
BRK inhibitor P21d hydrochloride is a potent breast tumor kinase (BRK/PTK6) inhibitor with an IC50 of 30 nM. BRK inhibitor P21d hydrochloride inhibits p-SAM68 with an IC50 of 52 nM. BRK inhibitor P21d hydrochloride can be used to evaluate the in vivo activity of BRK inhibitors in xenograft breast tumor models.
|
-
- HY-128859
-
|
EMT inhibitor-2
|
Cytochrome P450
|
Metabolic Disease
|
|
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively.
|
-
- HY-136279
-
|
TrxR inhibitor D9
|
Apoptosis
|
Cancer
|
|
TrxR inhibitor D9 is a potent and selective inhibitor of thioredoxin reductase (TrxR), with an EC50 of 2.8 nM. TrxR inhibitor D9 has the capability to inhibit tumor proliferation both in vitro and in vivo.
|
-
- HY-101297
-
|
Z-IETD-FMK
Z-IE(OMe)TD(OMe)-FMK
|
Caspase
|
Cancer
|
|
Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell permeable caspase-8 inhibitor. Z-IETD-FMK is also a granzyme B inhibitor.
|
-
- HY-100732
-
|
Cambinol
|
Sirtuin
Apoptosis
Phospholipase
|
Cancer
|
|
Cambinol is a SIRT1 and SIRT2 inhibitor with IC50 values of 56 μM and 59 μM, respectively. Cambinol is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
|
-
- HY-128917
-
-
- HY-15182
-
-
- HY-112474
-
-
- HY-119372
-
-
- HY-13662
-
-
- HY-13662A
-
-
- HY-128617
-
|
Legumain inhibitor 1
|
Others
|
Cancer
|
|
Legumain inhibitor 1 is a potent and selective Legumain inhibitor with an IC50 of 3.6 nM. Legumain inhibitor 1 can be used for cancer research.
|
-
- HY-119937
-
-
- HY-15253
-
-
- HY-112390A
-
|
Syk Inhibitor II
|
Syk
5-HT Receptor
|
Inflammation/Immunology
|
|
Syk Inhibitor II is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect.
|
-
- HY-122723
-
|
GOT1 inhibitor-1
|
Others
|
Cancer
|
|
GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC50 of 8.2 uM. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC).
|
-
- HY-13973A
-
-
- HY-104051
-
-
- HY-111347A
-
-
- HY-131100
-
-
- HY-135890
-
-
- HY-15444
-
-
- HY-114317
-
|
MARK4 inhibitor 1
|
Apoptosis
|
Cancer
|
|
MARK4 inhibitor 1 is a potent microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM. MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis.
|
-
- HY-15002
-
|
AST 487
NVP-AST 487
|
RET
FLT3
VEGFR
c-Kit
Bcr-Abl
|
Cancer
|
|
AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM.
|
-
- HY-135864
-
|
KRAS inhibitor-6
|
Ras
|
Cancer
|
|
KRAS inhibitor-6 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound A.
|
-
- HY-135866
-
|
KRAS inhibitor-8
|
Ras
|
Cancer
|
|
KRAS inhibitor-8 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound C.
|
-
- HY-135826
-
|
Necroptosis-IN-1
|
RIP kinase
|
Cancer
|
|
Necroptosis-IN-1, an analog of Necrostatin-1 (HY-15760), is a potent necroptosi inhibitor. Necroptosis-IN-1 is a RIPK inhibitor.
|
-
- HY-111408
-
-
- HY-N2033
-
-
- HY-100463
-
-
- HY-135865
-
|
KRAS inhibitor-7
|
Ras
|
Cancer
|
|
KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B.
|
-
- HY-112607
-
|
Tubulin inhibitor 1
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 1 is a tubulin inhibitor, inhibits tubulin polymerization. Tubulin inhibitor 1 shows potent anti-tumor activity, casues cellular mitotic arrest in the G2/M phase, and induces cellular apoptosis.
|
-
- HY-124798
-
-
- HY-32018
-
|
Cot inhibitor-2
|
MAP3K
|
Cancer
|
|
Cot inhibitor-2 is a potent, selective and orally active cot (Tpl2/MAP3K8) inhibitor with an IC50 of 1.6 nM. Cot inhibitor-2 inhibts TNF-α production in LPS-stimulated human whole blood with an IC50 of 0.3 μM.
|
-
- HY-118810
-
-
- HY-B0884
-
-
- HY-112569
-
-
- HY-B0884A
-
-
- HY-15167
-
-
- HY-112906
-
-
- HY-50856A
-
-
- HY-104022
-
-
- HY-117262
-
-
- HY-U00410
-
-
- HY-13276
-
-
- HY-B0218
-
-
- HY-106067A
-
-
- HY-N6717
-
|
Tentoxin
|
Others
|
Infection
|
|
Tentoxin is a cyclic tetrapeptide isolated from Alternaria tenuis, acts as a herbicide, causes seedling chlorosis, inhibits cyclic photophosphorylation and functions as an energy transfer inhibitor.
|
-
- HY-17542
-
|
PLpro inhibitor
|
SARS-CoV
|
Infection
|
|
PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM. PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 µM and an EC50 of 21.0 µM.
|
-
- HY-126328
-
|
PKC-theta inhibitor 1
|
PKC
|
Inflammation/Immunology
|
|
PKC-theta inhibitor 1 is the PKCθ inhibitor with an Ki value of 6 nM, inhibits IL-2 production in vivo with an IC50 of 0.19 μM. PKC-theta inhibitor 1 demonstrates a reduction of symptoms in a mouse model of multiple sclerosis.
|
-
- HY-15760
-
-
- HY-N1504
-
|
Loureirin B
|
PAI-1
Potassium Channel
ERK
JNK
|
Metabolic Disease
|
|
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.
|
-
- HY-13662B
-
|
(R)-Lansoprazole
Dexlansoprazole
|
Proton Pump
|
Inflammation/Immunology
|
|
(R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
|
-
- HY-131705
-
-
- HY-10217
-
-
- HY-P1029
-
-
- HY-15604
-
-
- HY-N0565
-
-
- HY-15183
-
-
- HY-U00387
-
-
- HY-107986
-
-
- HY-10249A
-
-
- HY-100962
-
|
(E)-AG 99
(E)-Tyrphostin 46; (E)-Tyrphostin AG 99
|
EGFR
|
Cancer
|
|
(E)-AG 99 ((E)-Tyrphostin 46) is a potent EGFR inhibitor.
|
-
- HY-N0565A
-
-
- HY-108322
-
-
- HY-112270
-
-
- HY-50880
-
-
- HY-N2221
-
-
- HY-14657
-
-
- HY-101932
-
-
- HY-N6902
-
-
- HY-U00319
-
-
- HY-15825
-
|
IWP L6
Porcn Inhibitor III
|
Porcupine
|
Cancer
|
|
IWP L6 (Porcn Inhibitor III) is a Porcn inhibitor with an EC50 of 0.5 nM.
|
-
- HY-15604A
-
-
- HY-112269
-
-
- HY-128723
-
-
- HY-50879
-
-
- HY-104032
-
-
- HY-10172
-
|
IMD-0354
IKK2 Inhibitor V
|
IKK
|
Cancer
|
|
IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM.
|
-
- HY-136270
-
|
ATR inhibitor 2
|
ATM/ATR
|
Cancer
|
|
ATR inhibitor 2 is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. ATR inhibitor 2 potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity.
|
-
- HY-103310
-
-
- HY-122856
-
|
AZ12601011
|
TGF-β Receptor
|
Cancer
|
|
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth .
|
-
- HY-50900
-
-
- HY-B0083
-
|
Leflunomide
HWA486; RS-34821; SU101
|
Others
|
Cancer
|
|
Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase, and acts as a disease-modifying antirheumatic drug.
|
-
- HY-101474A
-
|
Zanubrutinib
BGB-3111
|
Btk
|
Cancer
|
|
Zanubrutinib (BGB-3111) is a selective Bruton tyrosine kinase (Btk) inhibitor.
|
-
- HY-16569
-
-
- HY-N7592
-
|
Arjunetin
|
Others
|
Others
|
|
Arjunetin, isolated from Terminalia arjuna, is an insect feeding-deterrent and growth inhibitor.
|
-
- HY-W008923
-
-
- HY-12238
-
|
IWR-1
endo-IWR 1; IWR-1-endo
|
Wnt
|
Cancer
|
|
IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway.
|
-
- HY-100110
-
|
KNK437
Heat Shock Protein Inhibitor I
|
HSP
|
Cancer
|
|
KNK437 is a HSP inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.
|
-
- HY-135384
-
-
- HY-106638
-
-
- HY-101791
-
-
- HY-A0276
-
|
Gentamicin sulfate
|
Bacterial
Antibiotic
|
Infection
|
|
Gentamicin sulfate, an aminoglycoside antibiotic, inhibits the growth of both gram-positive and gram-negative bacteria and to inhibit several strains of mycoplasma in tissue culture. It inhibits DNase I with an IC50 of 0.57 mM.
|
-
- HY-N0518
-
|
Toddalolactone
|
PAI-1
|
Cardiovascular Disease
|
|
Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC50 value of 37.31 μM.
|
-
- HY-16657
-
-
- HY-19931
-
|
COH29
RNR Inhibitor COH29
|
DNA/RNA Synthesis
|
Cancer
|
|
COH29 (RNR Inhibitor COH29) is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity. COH29 inhibits α and β subunit of RNR with IC50s of 16 μM.
|
-
- HY-119808
-
-
- HY-128729
-
|
DNA2 inhibitor C5
|
Others
|
Cancer
|
|
DNA2 inhibitor C5 is a potent, competitive and specific inhibitor of DNA2 nuclease activity with an IC50 of 20 μM. DNA2 inhibitor C5 inhibits nuclease, DNA dependent ATPase, helicase, and DNA binding activities of DNA2. DNA2 inhibitor C5 is a promising lead compound to develop sensitizers for cancer chemotherapeutics that cause replication stress.
|
-
- HY-P2478
-
-
- HY-13624A
-
|
Epirubicin hydrochloride
4'-Epidoxorubicin hydrochloride
|
DNA/RNA Synthesis
Topoisomerase
Apoptosis
|
Cancer
|
|
Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.
|
-
- HY-P2477
-
-
- HY-15358
-
|
ALK inhibitor 2
|
ALK
FAK
|
Cancer
|
|
ALK inhibitor 2 (compound 18) is a potent pyrimidin ALK inhibitor. ALK inhibitor 2 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=37 nM) and focal adhesion kinase (FAK; IC50=5 nM).
|
-
- HY-10917
-
|
GW2580
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.
|
-
- HY-15357
-
|
ALK inhibitor 1
|
ALK
FAK
|
Cancer
|
|
ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=31 nM) and focal adhesion kinase (FAK; IC50=2 nM).
|
-
- HY-13624
-
|
Epirubicin
4'-Epidoxorubicin
|
DNA/RNA Synthesis
Topoisomerase
Apoptosis
|
Cancer
|
|
Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.
|
-
- HY-13417A
-
|
AICAR phosphate
Acadesine phosphate; AICA Riboside phosphate
|
AMPK
Autophagy
YAP
Mitophagy
|
Cancer
|
|
AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor.
|
-
- HY-113951
-
-
- HY-124718
-
|
p32 Inhibitor M36
M36
|
PKC
|
Cancer
|
|
p32 inhibitor M36 (M36) is a p32 mitochondrial protein inhibitor, which binds directly to p32 and inhibits p32 association with LyP-1.
|
-
- HY-13417
-
|
AICAR
Acadesine; AICA Riboside
|
AMPK
Autophagy
YAP
Mitophagy
|
Cancer
|
|
AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and mitophagy inhibitor.
|
-
- HY-B0113A
-
|
Omeprazole sodium
H 16868 sodium
|
Proton Pump
Autophagy
Bacterial
Phospholipase
|
Cancer
Infection
Metabolic Disease
|
|
Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria. Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
|
-
- HY-12072
-
|
Lck Inhibitor
|
Src
|
Inflammation/Immunology
|
|
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC50s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis.
|
-
- HY-P1398
-
-
- HY-P1260
-
-
- HY-19797A
-
-
- HY-14274
-
|
Anastrozole
ZD1033
|
Aromatase
|
Cancer
|
|
Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM.
|
-
- HY-131101
-
|
Nor-Acetildenafil
|
Others
|
Others
|
|
Nor-Acetildenafil is an Acetildenafil derivative. Acetildenafil is a synthetic agent which acts as a phosphodiesterase inhibitor.
|
-
- HY-10846
-
-
- HY-18930
-
|
NU6300
|
CDK
|
Cancer
|
|
NU6300 is the first covalent, irreversible and ATP-competitive CDK2 inhibitor.
|
-
- HY-W013478
-
-
- HY-10451S
-
-
- HY-15700
-
-
- HY-101429
-
|
RG13022
Tyrphostin RG13022
|
EGFR
|
Cancer
|
|
RG13022 is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC50 of 4 μM.
|
-
- HY-B1877
-
|
Nitrofen
|
Others
|
Cancer
|
|
Nitrofen is a selective contact herbicide. Nitrofen is a retinal dehydrogenase and protoporphyrinogen oxidase inhibitor.
|
-
- HY-N2219
-
-
- HY-19795
-
|
ML240
|
p97
|
Cancer
|
|
ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
|
-
- HY-112639
-
-
- HY-112913
-
-
- HY-100600
-
|
BGG463
K03859
|
CDK
|
Others
|
|
BGG463 (K03859) is an orally active type II CDK2 inhibitor.
|
-
- HY-N2117
-
|
Isoginkgetin
|
MMP
|
Cancer
|
|
Isoginkgetin is a MMP-9 inhibitor, also a Pre-mRNA Splicing Inhibitor with IC 50 of 30 uM.
|
-
- HY-136461
-
-
- HY-P2564
-
-
- HY-15222
-
-
- HY-14196
-
-
- HY-17396
-
-
- HY-14440
-
|
MP7
PDK1 inhibitor
|
PDK-1
|
Cancer
|
|
MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.
|
-
- HY-50670
-
-
- HY-U00145
-
-
- HY-10255A
-
|
Sunitinib
SU 11248
|
VEGFR
PDGFR
IRE1
Mitophagy
Autophagy
Apoptosis
|
Cancer
|
|
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
|
-
- HY-114309
-
-
- HY-111429
-
|
YAP/TAZ inhibitor-1
|
YAP
|
Cancer
|
|
YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC50 of <0.100 μΜ in firefly luciferase assay.
|
-
- HY-120859A
-
|
Zidebactam sodium salt
WCK-5107 sodium salt
|
Bacterial
|
Infection
|
|
Zidebactam sodium salt (WCK-5107 sodium salt) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL.
|
-
- HY-120859
-
|
Zidebactam
WCK-5107
|
Bacterial
|
Infection
|
|
Zidebactam (WCK-5107) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL.
|
-
- HY-118355
-
|
ALLM
Calpain inhibitor II
|
Proteasome
Cathepsin
|
Neurological Disease
|
|
ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI).
|
-
- HY-126331
-
-
- HY-12824
-
|
RNPA1000
|
Antibiotic
Bacterial
|
Infection
|
|
RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity.
|
-
- HY-101019
-
|
Ossirene
AS101
|
Interleukin Related
Caspase
|
Cancer
Inflammation/Immunology
|
|
Ossirene (AS101), an immunomodulatory tellurium compound, is a potent IL-1β inhibitor. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene potently inhibits Caspase-1 and is used for the autoimmune diseases and certain malignancies.
|
-
- HY-100932
-
|
ML-9
|
Myosin
|
Cancer
|
|
ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
|
-
- HY-B0113
-
|
Omeprazole
H 16868
|
Proton Pump
Autophagy
Bacterial
Phospholipase
|
Cancer
Infection
Metabolic Disease
|
|
Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
|
-
- HY-N0565B
-
|
Doxycycline (hyclate)
Doxycycline hydrochloride hemiethanolate hemihydrate; WC2031
|
Antibiotic
MMP
Bacterial
|
Infection
|
|
Doxycycline (hyclate) (Doxycycline hydrochloride hemiethanolate hemihydrate), an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor.
|
-
- HY-15699A
-
-
- HY-B2063
-
|
Chlorobenzuron
|
Others
|
Infection
|
|
Chlorobenzuron is a chitin synthetase inhibitor, acts as an insecticide. Chlorobenzuron can inhibit larvae development and pupate.
|
-
- HY-N1447
-
-
- HY-15167A
-
-
- HY-112634
-
-
- HY-133248
-
-
- HY-13972
-
-
- HY-15699
-
-
- HY-118165
-
-
- HY-B1596
-
-
- HY-P1260A
-
-
- HY-103593A
-
-
- HY-15842
-
-
- HY-103593
-
|
LCL521
|
Phospholipase
|
Cancer
|
|
LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase).
|
-
- HY-I0637
-
-
- HY-16187
-
-
- HY-133247
-
-
- HY-D0886
-
-
- HY-18965
-
-
- HY-12277
-
|
AZ191
|
DYRK
|
Cancer
|
|
AZ191 is a potent inhibitor that selectively inhibits DYRK1B with IC50 of 17 nM.
|
-
- HY-107451
-
-
- HY-107485
-
-
- HY-14174
-
-
- HY-N7511
-
-
- HY-N4294
-
-
- HY-B2007
-
-
- HY-100498
-
|
GSK2256098
|
FAK
Apoptosis
|
Cancer
|
|
GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
|
-
- HY-14445
-
-
- HY-19707
-
-
- HY-112822
-
|
ON-013100
|
CDK
|
Cancer
|
|
ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.
|
-
- HY-100456
-
-
- HY-111493
-
-
- HY-50706A
-
|
Selumetinib sulfate
AZD6244 sulfate; ARRY-142886 sulfate
|
MEK
Apoptosis
|
Cancer
|
|
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
|
-
- HY-105917
-
|
Endovion
NS3728
|
Chloride Channel
|
Others
|
|
Endovion (NS3728) is a pharmacological anion channel inhibitor (like chloride channel) and the specific VRAC/VSOAC blocker. Endovion (NS3728) is also an Anoctamin-1 (ANO 1) channel inhibitor.
|
-
- HY-10326
-
|
GW788388
|
TGF-β Receptor
|
Cancer
|
|
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
|
-
- HY-125997
-
|
BTK inhibitor 10
|
Btk
|
Inflammation/Immunology
|
|
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment.
|
-
- HY-13228
-
-
- HY-126288
-
|
ERK1/2 inhibitor 2
|
ERK
|
Cancer
|
|
ERK1/2 inhibitor 2 (Example 1) is a potent dual ERK1/2 inhibitor. ERK1/2 inhibitor 2 has anti-cancer activity.
|
-
- HY-16062
-
|
ARQ 621
|
Kinesin
|
Cancer
|
|
ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity. ARQ 621 is a kinesin inhibitor.
|
-
- HY-119935
-
-
- HY-10227
-
|
Bortezomib
PS-341; LDP-341; NSC 681239
|
Proteasome
NF-κB
Apoptosis
Autophagy
|
Cancer
|
|
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity.
|
-
- HY-10255
-
|
Sunitinib Malate
SU 11248 Malate
|
PDGFR
VEGFR
IRE1
Mitophagy
Autophagy
Apoptosis
|
Cancer
|
|
Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
|
-
- HY-17367
-
|
Atazanavir
BMS-232632
|
HIV
HIV Protease
Cytochrome P450
P-glycoprotein
|
Infection
Cancer
|
|
Atazanavir (BMS-232632) is a highly selective HIV-1 protease inhibitor for the treatment of HIV infection, and is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp).
|
-
- HY-N8533
-
|
Sodium Camptothecin
|
DNA/RNA Synthesis
|
Cancer
Infection
|
|
Sodium Camptothecin is a plant alkaloid, with antitumor activity. Sodium Camptothecin is a reversible inhibitor of RNA synthesis. Sodium Camptothecin is an effective inhibitor of adenovirus replication. Sodium Camptothecin inhibits DNA synthesis and, intracellularly, causes breaks in preformed viral DNA.
|
-
- HY-13985
-
-
- HY-12031A
-
-
- HY-U00453
-
-
- HY-112910
-
|
Grp94 Inhibitor-1
|
HSP
|
Cancer
Infection
|
|
Grp94 Inhibitor-1 is a potent, selective Grp94 inhibitor with an IC50 value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α.
|
-
- HY-15339
-
|
CVT-313
Cdk2 Inhibitor III
|
CDK
|
Cancer
|
|
CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 with IC50 of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation.
|
-
- HY-13984
-
|
Mutant EGFR inhibitor
|
EGFR
|
Cancer
|
|
Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1; inhibits EGFR L858R, EGFR Exon 19 deletion and EGFR T790M.
|
-
- HY-22166
-
-
- HY-W047428
-
-
- HY-112451
-
-
- HY-U00377
-
-
- HY-15217
-
-
- HY-15859
-
|
Atglistatin
|
ATGL
|
Metabolic Disease
|
|
Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.
|
-
- HY-77521
-
-
- HY-13502
-
-
- HY-119938
-
-
- HY-107994
-
-
- HY-70027A
-
-
- HY-N2567
-
|
(±)-Decursinol
|
Bacterial
|
Cancer
|
|
(±)-Decursinol is a potent FtsZ inhibitor. (±)-Decursinol inhibits B. anthracis FtsZ polymerization with an IC50 of 102 μM.
|
-
- HY-128962
-
-
- HY-13278
-
-
- HY-112860
-
-
- HY-A0116S
-
-
- HY-13060
-
-
- HY-101474
-
|
(±)-Zanubrutinib
(±)-BGB-3111
|
Btk
|
Cancer
|
|
(±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
|
-
- HY-124594
-
-
- HY-19731
-
-
- HY-101462
-
-
- HY-B0902A
-
|
Rufloxacin hydrochloride
MF-934 hydrochloride
|
Bacterial
|
Infection
|
|
Rufloxacin hydrochloride (MF-934 hydrochloride) is a fluoroquinolone antibacterial, inhibits B-cell differentiation in human mononuclear cells, inhibits Topo.
|
-
- HY-101963
-
-
- HY-115213
-
-
- HY-70073
-
-
- HY-15775
-
-
- HY-13502A
-
-
- HY-W010538
-
-
- HY-70003
-
-
- HY-112720
-
-
- HY-116767
-
|
BLT-1
Block lipid transport-1
|
HCV
|
Metabolic Disease
Inflammation/Immunology
|
|
BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor.
|
-
- HY-10439
-
|
HPGDS inhibitor 1
|
PGE synthase
|
Inflammation/Immunology
|
|
HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX.
|
-
- HY-P1111
-
|
Lyn peptide inhibitor
|
Src
Interleukin Related
|
Inflammation/Immunology
|
|
Lyn peptide inhibitor is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor can be used for study of asthma, allergic, and other eosinophilic disorders.
|
-
- HY-100932A
-
|
ML-9 Free Base
|
Myosin
|
Cancer
|
|
ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
|
-
- HY-135318
-
|
NBDHEX
|
Glutathione Peroxidase
Apoptosis
Autophagy
|
Cancer
|
|
NBDHEX is a potent glutathione S-transferase P1-1 (GSTP1-1) inhibitor. NBDHEX induces apoptosis of tumor cells. NBDHEX acts as an anticancer agent by inhibiting GSTs catalytic activity, avoiding inconvenience of the inhibitor extrusion from the cell by specific pumps and disrupting the interaction between the GSTP1-1 and key signaling effectors. NBDHEX can also act as late-phase autophagy inhibitor.
|
-
- HY-121172
-
|
1,4-DPCA
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
1,4-DPCA, a potent prolyl-4-hydroxylase inhibitor, is a collagen hydroxylation inhibitor in human foreskin fibroblasts with an IC50 of 2.4 µM. 1,4-DPCA inhibits prolyl-4-hydroxylases α isoforms stabilizes HIF-1α protein. 1,4-DPCA also inhibits factor inhibiting HIF (FIH) with an IC50 of 60 μM.
|
-
- HY-N0822
-
|
Shikonin
C.I. 75535; Isoarnebin 4
|
Chloride Channel
Pyruvate Kinase
NF-κB
TNF Receptor
HIV
|
Cancer
|
|
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
|
-
- HY-100816
-
|
Rbin-1
Ribozinoindole-1
|
Phosphatase
|
Metabolic Disease
|
|
Rbin-1 is a potent, reversible, and specific chemical inhibitor of eukaryotic ribosome biogenesis. Rbin-1 inhibits the ATPase with GI50 of 136 nM. Rbin-1 is a potent and selective chemical inhibitor of Midasin (Mdn1).
|
-
- HY-120675
-
|
SSTC3
|
Casein Kinase
Wnt
|
Cancer
|
|
SSTC3 is a casein kinase 1α (CK1α) activator (Kd = 32 nM) that inhibits WNT signaling (EC50 = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors.
|
-
- HY-100556
-
|
Tie2 kinase inhibitor 1
|
Others
|
Cancer
|
|
Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM. Tie2 kinase inhibitor 1 has anti-cancer activity.
|
-
- HY-112715
-
-
- HY-14165
-
-
- HY-124793A
-
|
GAK inhibitor 49 hydrochloride
|
Others
|
Infection
|
|
GAK inhibitor 49 hydrochloride is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 hydrochloride also shows binding to RIPK2.
|
-
- HY-19727A
-
-
- HY-129167
-
-
- HY-128918
-
|
SIS17
|
HDAC
|
Others
|
|
SIS17 is a mammalian histone deacetylase 11 (HDAC 11) inhibitor with an IC50 value of 0.83 μM, inhibits the demyristoylation HDAC11 substrate, serine hydroxymethyl transferase 2, without inhibiting other HDACs.
|
-
- HY-124793
-
|
GAK inhibitor 49
|
Others
|
Infection
|
|
GAK inhibitor 49 is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 also shows binding to RIPK2.
|
-
- HY-B0879A
-
|
Suramin sodium salt
Suramin hexasodium salt
|
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Cancer
Infection
Cardiovascular Disease
|
|
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
|
-
- HY-B0879
-
|
Suramin
|
Phosphatase
Sirtuin
Reverse Transcriptase
Topoisomerase
SARS-CoV
Parasite
Apoptosis
|
Cancer
Infection
Cardiovascular Disease
|
|
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor.Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
|
-
- HY-P0081
-
-
- HY-133110
-
|
Afatinib N-Oxide
|
Others
|
Others
|
|
Afatinib N-Oxide is a impurity of Afatinib dimaleate in oxidative degradation. Afatinib dimaleate is an irreversible EGFR family inhibitor.
|
-
- HY-15798
-
-
- HY-114418
-
-
- HY-N5038
-
|
Mauritianin
|
Topoisomerase
|
Cancer
|
|
Mauritianin is a kaempferol glycoside isolated from the flowers and leaves of Acalypha indica. Mauritianin is a topoisomerase I inhibitor.
|
-
- HY-13606
-
|
Dacinostat
NVP-LAQ824; LAQ824
|
HDAC
Autophagy
|
Cancer
|
|
Dacinostat is a potent HDAC inhibitor, with an IC50 of 32 nM; Dacinostat also inhibits HDAC1 with an IC50 of 9 nM, and used in cancer research.
|
-
- HY-13256
-
-
- HY-P1452A
-
-
- HY-Y0882
-
-
- HY-16420
-
|
R112
|
Syk
|
Inflammation/Immunology
|
|
R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.
|
-
- HY-111919
-
-
- HY-15588
-
-
- HY-B0830
-
|
Isoprocarb
|
AChE
|
Neurological Disease
|
|
Isoprocarb is carbamate insecticide that widely used to control rice paddy lice and leafhopper. Isoprocarb is also an AChE inhibitor.
|
-
- HY-N1502
-
|
Carboxyatractyloside
Gummiferin
|
Others
|
Cancer
|
|
Carboxyatractyloside is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport.
|
-
- HY-12054A
-
-
- HY-114423
-
-
- HY-16931
-
|
SMIFH2
|
Others
|
Cancer
|
|
SMIFH2 is a formin specific inhibitor. SMIFH2 inhibits actin polymerization by Formins and affects the actin cytoskeleton.
|
-
- HY-10809
-
|
Bitopertin
RG1678; RO4917838
|
GlyT
|
Neurological Disease
|
|
Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human GlyT1 with a concentration exhibiting IC50 of 25 nM.
|
-
- HY-19609
-
-
- HY-131268
-
-
- HY-N6619A
-
|
Lycoramine
|
AChE
|
Neurological Disease
|
|
Lycoramine, a dihydro-derivative of galanthamine, is isolated from Lycoris radiate. Lycoramine is a potent acetylcholinesterase (AChE) inhibitor.
|
-
- HY-104028
-
-
- HY-12814A
-
-
- HY-12814
-
|
TH588
|
DNA/RNA Synthesis
|
Cancer
|
|
TH588 is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC50= 5 nM).
|
-
- HY-111506
-
-
- HY-12420
-
|
JNJ-47117096 hydrochloride
MELK-T1 hydrochloride
|
MELK
FLT3
|
Cancer
|
|
JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.
|
-
- HY-16982
-
|
Cercosporamide
(-)-Cercosporamide
|
Fungal
MNK
|
Cancer
Infection
|
|
Cercosporamide is a highly potent, ATP-competitive Pkc1 kinase inhibitor, with an IC50 of <50 nM and a Ki of <7 nM. Cercosporamide is a unique Mnk inhibitor.
|
-
- HY-136347
-
-
- HY-13280
-
-
- HY-18928
-
|
FAK inhibitor 5
|
FAK
|
Cancer
|
|
FAK inhibitor 5 (compound 2) is a novel allosteric FAK inhibitor, with IC50 values in the low micromolar range.
|
-
- HY-N4186
-
-
- HY-103002
-
|
SU5408
VEGFR2 Kinase Inhibitor I
|
VEGFR
|
Cardiovascular Disease
|
|
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC50 of 70 nM.
|
-
- HY-B0497B
-
-
- HY-131446
-
|
Chk1-IN-5
|
Checkpoint Kinase (Chk)
|
Cancer
|
|
Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model.
|
-
- HY-50202
-
|
Etomoxir
(R)-(+)-Etomoxir
|
Apoptosis
|
Cancer
Metabolic Disease
|
|
Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
|
-
- HY-50202A
-
|
Etomoxir sodium salt
(R)-(+)-Etomoxir sodium salt
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Etomoxir sodium salt ((R)-(+)-Etomoxir sodium salt) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
|
-
- HY-117491
-
-
- HY-124416
-
|
ML604086
|
CCR
|
Inflammation/Immunology
Endocrinology
|
|
ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca 2+ concentrations.
|
-
- HY-103490
-
|
Takinib
|
MAP3K
Apoptosis
|
Cancer
|
|
Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, which inhibits autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation.
|
-
- HY-17367A
-
|
Atazanavir sulfate
BMS-232632 sulfate
|
HIV
HIV Protease
Cytochrome P450
P-glycoprotein
|
Cancer
Infection
|
|
Atazanavir sulfate (BMS-232632 sulfate) is a highly selective HIV-1 protease inhibitor for the treatment of HIV infection, and is the first protease inhibitor approved for once-daily administration. Atazanavir sulfate (BMS-232632 sulfate) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp).
|
-
- HY-122866
-
|
ZT-12-037-01
|
Ras
|
Cancer
|
|
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM.
|
-
- HY-109574
-
|
Raf inhibitor 2
|
Raf
|
Cancer
|
|
Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research.
|
-
- HY-100227
-
|
E 64c
|
Cathepsin
SARS-CoV
|
Metabolic Disease
|
|
E 64c is a derivative of naturally occurring epoxide inhibitor of cysteine proteases, a Calcium-activated neutral protease (CANP) inhibitor and a very weak irreversible cathepsin C inhibitor. E 64c exhibits entry-blocking effect for MERS-CoV.
|
-
- HY-66004
-
|
4-Acetamidophenyl acetate
|
Others
|
Inflammation/Immunology
|
|
4-Acetamidophenyl acetate is an impurity of Acetaminophen (paracetamol). Acetaminophen, an analgesic drug, is a selective COX-2 inhibitor (IC50=25.8 μM), and is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.
|
-
- HY-115502
-
|
BCI
(E)-BCI
|
Phosphatase
|
Cancer
Inflammation/Immunology
|
|
BCI is an allosteric inhibitor of dual specificity phosphatase (DUSP). BCI specifically inhibits DUSP6 and DUSP1 with EC50s of 13.3 and 8.0 μM in cells, respectively. BCI does not inhibit DUSP5.
|
-
- HY-80003
-
|
QL47
|
Btk
|
Cancer
Infection
|
|
QL47, a broad-spectrum antiviral agent, inhibits dengue virus and other RNA viruses. QL47 selectively inhibits eukaryotic translation. QL47 is a potent covalent inhibitor of BTK with an IC50 of 7 nM.
|
-
- HY-133019
-
-
- HY-P1045
-
|
187-1, N-WASP inhibitor
|
Arp2/3 Complex
|
Others
|
|
187-1, N-WASP inhibitor, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.
|
-
- HY-124653
-
|
HSP27 inhibitor J2
J2
|
HSP
|
Cancer
|
|
HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition.
|
-
- HY-P1045A
-
|
187-1, N-WASP inhibitor TFA
|
Arp2/3 Complex
|
Others
|
|
187-1, N-WASP inhibitor TFA, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor TFA potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor TFA prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.
|
-
- HY-P1111A
-
|
Lyn peptide inhibitor TFA
|
Src
Interleukin Related
|
Inflammation/Immunology
|
|
Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of asthma, allergic, and other eosinophilic disorders.
|
-
- HY-15766A
-
|
GNE-617 hydrochloride
|
NAMPT
|
Cancer
|
|
GNE-617 hydrochloride is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer.
|
-
- HY-12399
-
|
MKC9989
|
IRE1
|
Cancer
|
|
MKC9989 is a Hydroxy aryl aldehydes (HAA) inhibitor and also inhibits IRE1α with an IC50 of 0.23 to 44 μM.
|
-
- HY-112280
-
-
- HY-10247
-
|
BRAF inhibitor
|
Raf
|
Cancer
|
|
BRAF inhibitor is a B-Raf inhibitor extracted from patent WO/2011103196 A1, Compound P-0850.
|
-
- HY-12726A
-
-
- HY-N2522
-
-
- HY-109565
-
|
ASTX660
|
IAP
|
Cancer
|
|
ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).
|
-
- HY-108820
-
-
- HY-108817
-
-
- HY-10978
-
-
- HY-13452
-
-
- HY-119459
-
|
Fluopyram
|
Fungal
|
Infection
|
|
Fluopyram is a succinate dehydrogenase inhibitor fungicide, inhibits the growth of F. virguliforme isolates with mean EC50 of 3.35 µg/mL.
|
-
- HY-10162S
-
-
- HY-U00370
-
-
- HY-111489A
-
-
- HY-17421A
-
-
- HY-135383A
-
-
- HY-128977
-
-
- HY-12000
-
|
AG490
Tyrphostin AG490; Tyrphostin B42
|
EGFR
STAT
JAK
Autophagy
|
Cancer
|
|
AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
|
-
- HY-A0122
-
-
- HY-111446
-
-
- HY-17381
-
-
- HY-N6031
-
|
Dendrophenol
|
NF-κB
|
Cancer
|
|
Dendrophenol, isolated from the stem of Dendrobium loddigesii Rolfe, act as a NF-κB inhibitor. Antineoplastic activity.
|
-
- HY-Y0172
-
-
- HY-13026S
-
|
Idelalisib D5
CAL-101 D5; GS-1101 D5
|
PI3K
Autophagy
|
Cancer
|
|
Idelalisib D5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor.
|
-
- HY-108941
-
|
Salicyl-AMS
|
Bacterial
|
Infection
|
|
Salicyl-AMS is a mycobactin biosynthesis inhibitor which can also inhibit M. tuberculosis growth in vitro under iron-limited conditions.
|
-
- HY-15282
-
-
- HY-B0806
-
|
Proguanil
|
Parasite
Antifolate
|
Infection
|
|
Proguanil, an antimalarial prodrug, is metabolized to the active metabolite Cycloguanil (HY-12784). Proguanil is a dihydrofolate reductase (DHFR) inhibitor.
|
-
- HY-N2597
-
-
- HY-B0806A
-
-
- HY-112297
-
-
- HY-13420
-
-
- HY-100736
-
|
ML348
GNF-Pf-1127
|
Phospholipase
|
Cancer
|
|
ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor with an IC50 of 210 nM, and barely inhibits LYPLA2.
|
-
- HY-15202
-
|
Binimetinib
MEK162; ARRY-162; ARRY-438162
|
MEK
Autophagy
|
Cancer
|
|
Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
|
-
- HY-102007
-
|
Gamitrinib TPP
|
HSP
|
Cancer
|
|
Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.
|
-
- HY-12726
-
-
- HY-N1724
-
-
- HY-15766
-
|
GNE-617
|
NAMPT
|
Metabolic Disease
Cancer
|
|
GNE-617 is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer.
|
-
- HY-111489B
-
-
- HY-126253
-
|
BI-4916
|
Others
|
Cancer
|
|
BI-4916 is a prodrug of BI-4924. BI-4924 is a NADH/NAD +-competitive PHGDH inhibitor.
|
-
- HY-136485
-
-
- HY-B1863
-
|
Iprobenfos
|
Fungal
|
Infection
|
|
Iprobenfos is an organophosphorus fungicide and is widely used to control the rice blast fungus. Iprobenfos is also a choline biosynthesis inhibitor.
|
-
- HY-B0882
-
|
Edrophonium chloride
|
AChE
|
Neurological Disease
|
|
Edrophonium chloride is a readily reversible acetylcholinesterase inhibitor; prevents breakdown of the neurotransmitter acetylcholine and acts by competitively inhibiting the enzyme acetylcholinesterase, mainly at the neuromuscular junction.
|
-
- HY-135899
-
|
SIRT7 inhibitor 97491
|
Sirtuin
Apoptosis
|
Cancer
|
|
SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway..
|
-
- HY-B2145
-
|
Ilaprazole sodium
IY-81149 sodium
|
Proton Pump
TOPK
|
Cancer
Inflammation/Immunology
|
|
Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.
|
-
- HY-107412
-
|
Proteasome inhibitor IX
PS-IX; AM114
|
Proteasome
|
Cancer
|
|
Proteasome inhibitor IX (PS-IX; AM114) is a Chalcone derivative and a chymotrypsin-like activity of the 20S proteasome inhibitor with an IC50 value of ~1 μM. Proteasome inhibitor IX exhibits HCT116 p53 +/+ cells growth inhibitory activity with an IC50 value of 1.49 μM. Proteasome inhibitor IX has potent anticancer activity.
|
-
- HY-130795
-
|
GSK-3β inhibitor 2
|
GSK-3
|
Neurological Disease
|
|
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease.
|
-
- HY-10255AS
-
|
Sunitinib D10
SU 11248 D10
|
VEGFR
PDGFR
IRE1
Mitophagy
Autophagy
Apoptosis
|
Cancer
|
|
Sunitinib D10 (SU 11248 D10) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
|
-
- HY-124726
-
|
Aumitin
|
Autophagy
|
Cancer
Neurological Disease
|
|
Aumitin is a diaminopyrimidine-based autophagy inhibitor which inhibits mitochondrial respiration by targeting complex I. Aumitin inhibits starvation- and rapamycin induced autophagy dose dependently with IC50s of 0.12 μM and 0.24 μM, respectively.
|
-
- HY-19727
-
-
- HY-N7674A
-
|
Angoline hydrochloride
|
STAT
|
Cancer
|
|
Angoline hydrochloride is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
|
-
- HY-P1290
-
|
PKA Inhibitor Fragment (6-22) amide
PKI-(6-22)-amide
|
PKA
|
Neurological Disease
|
|
PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice.
|
-
- HY-N7674
-
|
Angoline
|
STAT
|
Cancer
|
|
Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
|
-
- HY-109019
-
|
Vorolanib
CM082; X-82
|
VEGFR
PDGFR
|
Cancer
Cardiovascular Disease
|
|
Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895).
|
-
- HY-12054
-
|
Hesperadin
|
Aurora Kinase
Autophagy
Influenza Virus
Parasite
|
Cancer
|
|
Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC50 of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral.
|
-
- HY-100734
-
